Safety, pharmacokinetic, pharmacodynamic and clinical activity of molibresib for the treatment of NUT carcinoma and other cancers: results of a phase I/II open-label, dose escalation study.
Sign Up to like & getrecommendations! Published in 2021 at "International journal of cancer"
DOI: 10.1002/ijc.33861
Abstract: Molibresib is an orally bioavailable, selective, small molecule BET protein inhibitor. Results from a first time in human study in solid tumors resulted in the selection of a 75 mg once daily dose of the besylate… read more here.
Keywords: clinical activity; safety; molibresib; cancer ... See more keywords